GHRP-6 Reconstitution Calculator

No. GHRP-6 has no regulatory approval in any jurisdiction for therapeutic or performance use; it circulates as an unregulated "research compound". Formal clinical development is limited to an intravenous EGF+GHRP-6 combination in acute ischemic stroke: a phase I/II trial (75 µg EGF + 3.5–5 mg GHRP-6 twice daily ×7 days) found acceptable safety with favorable functional trends; the phase III COURAGE-2 trial missed its primary endpoint but improved 6-month outcomes in severe stroke (mRS 2.6 vs 4.7, p=0.03; mortality HR 0.18). GHRP-6 is WADA-prohibited and detectable in urine, largely as unchanged parent for ~23 h after dosing, with metabolites visible ~12 h.

Subcutaneous injection is the standard self-administered route at 100–300 mcg, 1–3×/day, typically fasted (community protocol). Diagnostic testing uses 1 µg/kg IV, producing mean GH peaks of 25.7 µg/L in GH-sufficient adults. Oral absorption is inefficient: 300 µg/kg orally in children (~21 mg for a 70 kg adult) was required to match maximal IV GHRH (peak 18.8 vs 20.8 µg/L). Intranasal GHRP-6 (5 mg/kg in mice) raised GH and activated arcuate AgRP/NPY neurons. Injection remains the practical route given oral-dose requirements.

Yes, it directly activates appetite (orexigenic) circuitry. Intranasal GHRP-6 increased food intake via more and larger meals, with neuronal c-Fos coexpressed in ghrelin-receptor (Ghsr) and AgRP arcuate neurons; appetite change is among the most-reported effects in users. Fasted dosing before meals exploits this signal; those wanting appetite suppression generally avoid GHRP-6 (community protocol).

The consistent human finding is concomitant ACTH and cortisol elevation, alongside increased slow-wave sleep and GH. In diagnostic testing, transient facial flushing was the only reported side effect. Across growth hormone secretagogue users, reported effects include prolactin and cortisol elevations, fluid retention, arthralgia/myalgia, dysglycaemia, and injection-site reactions. Toxicology is reassuring: 28 days of daily IV dosing in dogs up to 2000 µg/kg/day caused only transient hypersalivation, hypoactivity, and reduced heart rate; NOAEL was 2000 µg/kg/day.

Repeated boluses produce a cyclic pattern of GH responsiveness: dosing every 60–90 min yields highly variable responses, while spacing injections ≥3 h restores consistent GH release. Community practice is 8–12-week cycles with off periods (community protocol). No long-term human safety trials exist. One case report describes ~20 years of GH secretagogue use (somatropin plus sermorelin/GHRP-6) with symptomatic cervical osteophytes and dysphagia, a hypothesized, unproven association.

GHRP-2 raises intracellular cAMP and is sensitive to GRF-receptor blockade, whereas GHRP-6 releases GH without elevating cAMP via Ca²⁺-dependent signaling, evidence for distinct receptor subtypes. GHRP-6 uniquely shows CD36 scavenger receptor binding, the basis of its preclinical cardioprotective, cytoprotective, and antifibrotic profile. Ipamorelin is regarded as more GHSR-selective with lower ACTH/cortisol elevation (community consensus).

No human data exist; avoid it. In mice, ovarian hyperstimulation raises circulating ghrelin and delays preimplantation embryo development, and this was reversed by the ghrelin-receptor blocker D-Lys3-GHRP-6. Since GHRP-6 is a GHSR agonist, this argues for conservative avoidance during pregnancy and assisted reproduction (mechanistic).

Yes. Thermal-stress studies show C-terminal deamidation at pH 3 and pH 8, hydrolysis and head-to-tail cyclization at pH 6–7, tryptophan oxidation products, and buffer-induced acylation. Practical handling: refrigerate lyophilized and reconstituted vials, reconstitute with bacteriostatic water, avoid warm neutral-pH storage and phosphate buffers, and use within days-to-weeks of reconstitution (community protocol).